CTOs on the Move

Genesys Spine

www.genesysspine.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.genesysspine.com
  • 1250, South Capital of Texas Highway
    Austin, TX USA 78746
  • Phone: 512.381.7070

Executives

Name Title Contact Details

Similar Companies

Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Our products are helping to address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. We are improving people’s quality of life by preventing, alleviating or curing diseases. We are helping to provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. In line with our mission “Bayer: Science For A Better Life”, we aim to improve people’s quality of life. For this endeavor, we focus on our core competency of developing and successfully commercializing innovative products and solutions based on scientific knowledge.

A and J Consulting Engineering Services, PC

A and J Consulting Engineering Services, PC is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

Oxis International

Oxis International, Inc. has formed and provided initial financing to support the activities of its wholly owned subsidiary, Oxis Biotech, Inc. The parent company, Oxis International is engaged in the research, development and sale of products to counteract oxidative stress and inflammation. Oxis Biotech is focused on the acquisition of cannabis related intellectual properties and commercialization of therapies developed from the intellectual properties to treat certain diseases.